| Deler fremragende | 11,627,118 shares |
| Insideraktier | 53.227.377 shares |
| Total Insiders | 41 |
Insider-stemningsscore
Insider Sentiment Score viser, at virksomhederne bliver købt af virksomheders insidere.
Det er resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af insider-akkumulering. Scoringsmodellen bruger en kombination af nettoantallet af insidere, der har købt de foregående 90 dage, det samlede antal aktier købt som en procentdel af float og det samlede antal aktier ejet af insidere. Tallet går fra 0 til 100, hvor højere tal indikerer et højere niveau af akkumulering for sine jævnaldrende, og 50 er gennemsnittet.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med den højeste insider-akkumulering.
Officers sentiment score
Officer Sentiment Score finder virksomheder, der bliver købt af Corporate Officers.
Per definition er Corporate Officers Corporate Insiders, men i modsætning til nogle af de andre Insiders (10 % aktionærer og bestyrelsesmedlemmer), arbejder officerer for virksomheden på daglig basis, og de bruger deres egne penge, når de handler . (10 % aktionærer og bestyrelsesmedlemmer er ofte fondsforvaltere, der administrerer andres penge.) Som sådan er insiderhandler foretaget af embedsmænd meget mere betydningsfulde og bør behandles passende.
Ligesom Insider Sentiment Score er Officer Sentiment Score resultatet af en sofistikeret, multi-faktor kvantitativ model, der identificerer virksomheder med de højeste niveauer af officerakkumulering.
Opdateringsfrekvens: Dagligt
Se Insiders Top Picks, som giver en liste over virksomheder med højeste insider-stemning.
Nøgle Insider Metrics
Dette kort viser, hvordan virksomheden rangerer langs forskellige insider-metrics. Percentilrangen viser, hvordan denne virksomhed sammenligner sig med andre virksomheder på de amerikanske markeder. Højere placeringer er tegn på bedre situationer.
For eksempel er det generelt accepteret, at insider-køb er en positiv indikator, så virksomheder med flere insider-køb vil rangere højere end virksomheder med mindre insider-køb (eller endda insider-salg).
Insiderhandelsdiagram
Adhera Therapeutics, Inc. insiderhandler er vist i følgende diagram. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Generelt er det generelt ulovligt for insidere at foretage handler i deres virksomheder baseret på væsentlige, ikke-offentlige oplysninger. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4.
Insiderliste og lønsomhedsmålinger
Denne tabel viser listen over kendte insidere og genereres automatisk fra arkiveringer, der er videregivet til SEC. Ud over navnene, den seneste titel og direktør, officer eller 10 % ejerbetegnelse giver vi de seneste offentliggjorte besiddelser. Derudover giver vi, når det er muligt, den historiske handelspræstation for insideren. Den historiske handelspræstation er et vægtet gennemsnit af præstationen af faktiske købstransaktioner på det åbne marked foretaget af insideren. For mere information om, hvordan dette beregnes, se dette YouTube-webinar.
See our leaderboard of most profitable insider traders.
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
|
Autotelic LLC
10% Owner -
|
46.247.116 | 46.247.116 | |
| Susan B Bayh Director - [D] | 20.235 | 20.235 | |
| J Carter Jr Beese Director - [D] | 12.500 | 12.500 | |
| Isaac Blech | 0 | ||
| Gordon Brandt Exec VP of Science and Clinica - [O] | 12.500 | 12.500 | |
| Timothy Boris | 0 | ||
| Alexander D Cross Director - [D] | 22.500 | 22.500 | |
| Philippe Calais | 80.000 | ||
| Henry R Costantino Chief Scientific Officer - [O] | 5.000 | 5.000 | |
| Timothy M Duffy Exec. VP of Business Devp - [O] | 35.052 | 35.052 | |
| Erik Emerson Chief Commercial Officer - [O] | 1.200.000 | 1.200.000 | |
| Ian R Ferrier Director - [D] | 9.235 | 9.235 | |
| J Michael French President and CEO, Director - [D] [O] | 822.283 | 822.283 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
| Myron Z Holubiak Director - [D] | 23.735 | 23.735 | |
| Uli Hacksell | 1.000.000 | ||
| Richard Theodore Ho Executive Vice President - R&D - [O] | 390.000 | 390.000 | |
| Larn Hwang | 0 | ||
| Paul H Johnson Sr VP of R&D, CSO - [O] | 11.500 | 11.500 | |
| Andrew Albert Kucharchuk | 0 | ||
| Chiang J Li Director - [D] | 62.395 | 62.395 | |
| Stefan Loren Director - [D] | 181.303 | 181.303 | |
| Leslie D Michelson Director - [D] | 37.000 | 37.000 | |
| Moscato Robert Jr. | 300.000 | ||
| Mihir Munsif | 60.000 | ||
| John V Pollock Director - [D] | 30.833 | 30.833 | |
| Peter Parker Director - [D] | 7.957 | 7.957 | |
| Phelan Nancy R. | 1.500.000 |
| Insider | Gennemsnitlig fortjeneste (%) | Aktier Ejet |
Dele Justeret |
|---|---|---|---|
|
Cashman LLP Pryor
10% Owner -
|
1.591.959 | 1.591.959 | |
| Ramelli Joseph W. Chief Executive Officer - [O] | 418.153 | 418.153 | |
| Philip C Ranker Former Interim CFO & Secretary, Director - [D] [O] | 897.553 | 897.553 | |
| Shah Amit B. | 0 | ||
| Gerald T Stanewick Director - [D] | 97.212 | 97.212 | |
| Stanley Rhonda L. | 350.000 | ||
| Bruce R/fa Thaw Director - [D] | 104.041 | 104.041 | |
| Robert Eric Teague | 100.000 | ||
|
Vuong Trieu
Director, 10% Owner -
[D]
|
612.716 | 612.716 | |
| Devin Wenig Director - [D] | 366.487 | 366.487 | |
| David E Wormuth Sr VP, Operations & Mfg - [O] | 7.500 | 7.500 | |
| Weinstein Peter D. | 0 | ||
| Donald Allen Williams | 135.000 | ||
| Bruce R York - | 612 | 612 |
Report errors via our new Insider Auditing Tool
Track Records af insiderkøb - Kortsigtet profitanalyse
I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i ATRX / Adhera Therapeutics, Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Track Records af insidersalg - Kortsigtet tabsanalyse
I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i ATRX / Adhera Therapeutics, Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .
Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.
Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.
Transaktionshistorik
Klik på linkikonet for at se den fulde transaktionshistorik. Transaktioner, der rapporteres som en del af en automatisk handelsplan 10b5-1, vil have et X i kolonnen markeret 10b-5.
| Fil Dato |
Handle Dato |
Form | Insider | Ticker | Sikkerhedstitel | Kode | Direkte | Dyrke motion Pris |
Enhed Pris |
Enheder Ændret |
Værdi Ændret (1K) |
Tilbage Muligheder |
Tilbage Aktier |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2019-11-05 | 2019-11-01 | 4 | Stanley Rhonda L. | ATRX | Options to purchase common stock | D | 0,09 | 350.000 | 350.000 | |||||
| 2019-04-04 | 2019-04-04 | 4 | Phelan Nancy R. | ATRX | Options to purchase common stock | D | 0,37 | 1.500.000 | 1.500.000 | |||||
| 2019-01-17 | 2019-01-15 | 4 | Teague Robert Eric | ATRX | Options to purchase common stock | D | 0,32 | 100.000 | 100.000 | |||||
| 2018-10-04 | 2018-10-01 | 4 | Trieu Vuong | MRNA | Common Stock | D | 0,5000 | -500.000 | -250 | 612.716 | ||||
| 2018-09-26 | 2018-09-24 | 4 | Teague Robert Eric | MRNA | Options to purchase common stock | D | 0,55 | 450.000 | 450.000 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Moscato Robert Jr. | MRNA | Warrants to Purchase Common Stock | I | 0,55 | 300.000 | 300.000 | |||||
| 2018-07-16 | 2018-07-12 | 4 | Moscato Robert Jr. | MRNA | Series F Convertible Preferred Stock | I | 0,50 | 5.000,0000 | 40 | 200 | 40 | |||
| 2018-07-12 | 2018-07-10 | 4 | Emerson Erik | MRNA | Options to purchase common stock | D | 0,66 | 1.125.000 | 1.125.000 | |||||
| 2018-07-11 | 2018-07-10 | 4 | Hacksell Uli | MRNA | Options to purchase common stock | D | 0,66 | 1.000.000 | 1.000.000 | |||||
| 2018-07-11 | 2018-07-10 | 4 | Moscato Robert Jr. | MRNA | Options to purchase common stock | D | 0,66 | 1.500.000 | 1.500.000 | |||||
| 2018-05-04 | 2018-05-02 | 4 | Ranker Philip C | MRNA | Options to purchase common stock | D | 0,98 | 200.000 | 200.000 | |||||
| 2018-05-04 | 2018-05-02 | 4 | Calais Philippe | MRNA | Options to purchase common stock | D | 0,98 | 80.000 | 80.000 | |||||
| 2018-05-04 | 2018-05-02 | 4 | Ramelli Joseph W. | MRNA | Options to purchase common stock | D | 0,98 | 100.000 | 100.000 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Ranker Philip C | MRNA | Warrants to Purchase Common Stock | D | 0,55 | 135.000 | 135.000 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Ranker Philip C | MRNA | Series E Convertible Preferred Stock | D | 0,50 | 5.000,0000 | 18 | 90 | 18 | |||
| 2018-04-18 | 2018-04-16 | 4 | BLECH ISAAC By trust | MRNA | Convertible Promissory Note | I | 5.000,00 | |||||||
| 2018-04-18 | 2018-04-16 | 4 | BLECH ISAAC By trust | MRNA | Warrants to Purchase Common Stock | I | 0,55 | 777.750 | 777.750 | |||||
| 2018-04-18 | 2018-04-16 | 4 | BLECH ISAAC By trust | MRNA | Series E Convertible Preferred Stock | I | 0,50 | 5.000,0000 | 104 | 518 | 104 | |||
| 2018-04-18 | 2018-04-16 | 4 | BLECH ISAAC | MRNA | Warrants to Purchase Common Stock | D | 0,55 | 16.875 | 16.875 | |||||
| 2018-04-18 | 2018-04-16 | 4 | BLECH ISAAC | MRNA | Series E Convertible Preferred Stock | D | 0,50 | 5.000,0000 | 2 | 11 | 2 | |||
| 2018-04-18 | 2018-04-16 | 4 | Williams Donald Allen | MRNA | Warrants to Purchase Common Stock | D | 0,55 | 135.000 | 135.000 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Williams Donald Allen | MRNA | Series E Convertible Preferred Stock | D | 0,50 | 5.000,0000 | 18 | 90 | 18 | |||
| 2018-04-18 | 2018-04-16 | 4 | Hwang Larn | MRNA | 5% Convertible Promissory Note | D | 5.000,00 | |||||||
| 2018-04-18 | 2018-04-16 | 4 | Hwang Larn | MRNA | Warrants to Purchase Common Stock | D | 0,55 | 78.300 | 78.300 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Hwang Larn | MRNA | Series E Convertible Preferred Stock | D | 0,50 | 5.000,0000 | 10 | 52 | 10 | |||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong By Autotelic Inc. | MRNA | Warrants to Purchase Common Stock | I | 0,55 | 2.564.465 | 2.564.465 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong By Autotelic Inc. | MRNA | Series E Convertible Preferred Stock | I | 0,50 | 5.000,0000 | 163 | 813 | 163 | |||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | 5% Convertible Promissory Note | D | 5.000,00 | |||||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong By Autotelic Inc. | MRNA | 5% Demand Line of Credit | I | 5.000,00 | |||||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong By Autotelic Inc. | MRNA | Warrants to Purchase Common Stock | I | 0,55 | 142.500 | 142.500 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong By Autotelic Inc. | MRNA | Series E Convertible Preferred Stock | I | 0,50 | 5.000,0000 | 19 | 95 | 19 | |||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | 5% Demand Line of Credit | D | 5.000,00 | |||||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | Warrants to Purchase Common Stock | D | 0,55 | 859.725 | 859.725 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | Series E Convertible Preferred Stock | D | 0,50 | 5.000,0000 | 115 | 573 | 115 | |||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | Warrants to Purchase Common Stock | D | 0,55 | 258.825 | 258.825 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | Series E Convertible Preferred Stock | D | 0,50 | 5.000,0000 | 35 | 173 | 35 | |||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | Warrants to Purchase Common Stock | D | 0,55 | 16.875 | 16.875 | |||||
| 2018-04-18 | 2018-04-16 | 4 | Trieu Vuong | MRNA | Series E Convertible Preferred Stock | D | 0,50 | 5.000,0000 | 2 | 11 | 2 | |||
| 2018-01-03 | 2018-01-03 | 4 | BLECH ISAAC | MRNA | Options to purchase common stock | D | 1,56 | 3.800 | 3.800 | |||||
| 2018-01-03 | 2018-01-03 | 4 | Calais Philippe | MRNA | Options to purchase common stock | D | 1,56 | 3.800 | 3.800 | |||||
| 2018-01-03 | 2018-01-03 | 4 | Ranker Philip C | MRNA | Options to purchase common stock | D | 1,56 | 3.800 | 3.800 | |||||
| 2018-01-03 | 2018-01-03 | 4 | Williams Donald Allen | MRNA | Options to purchase common stock | D | 1,56 | 3.800 | 3.800 | |||||
| 2018-01-03 | 2018-01-03 | 4 | Trieu Vuong | MRNA | Options to purchase common stock | D | 1,56 | 3.800 | 3.800 | |||||
| 2017-11-27 | 2017-11-22 | 4 | BLECH ISAAC | MRNA | Stock Option (Right to Buy) | D | 1,80 | 473.457 | 473.457 | |||||
| 2017-10-24 | 2017-10-12 | 4 | Weinstein Peter D. | MRNA | Options to purchase common stock | D | 2,40 | 60.000 | 60.000 | |||||
| 2017-10-06 | 2017-10-02 | 4 | Shah Amit B. | MRNA | Options to purchase common stock | D | 2,70 | 60.000 | 60.000 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Hwang Larn | MRNA | 5% Convertible Promissory Note | D | 0,35 | 50.000,0000 | 142.857 | |||||
| 2017-07-05 | 2017-06-30 | 4 | Trieu Vuong | MRNA | 5% Convertible Promissory Note | D | 0,35 | 165.634,0000 | 473.240 | |||||
| 2017-06-27 | 3 | Emerson Erik | MRNA | Common Stock | D | 1.200.000 | ||||||||
| 2017-06-27 | 3 | Emerson Erik | MRNA | Common Stock | D | 1.200.000 | ||||||||
| 2017-06-12 | 2017-06-09 | 4 | Trieu Vuong | MRNA | Common Stock | D | 0,3900 | 10.000 | 4 | 11.127.141 | ||||
| 2017-06-08 | 2017-06-08 | 4 | Trieu Vuong | MRNA | Common Stock | D | 0,3900 | 20.000 | 8 | 11.117.141 | ||||
| 2017-06-08 | 2017-06-07 | 4 | Trieu Vuong | MRNA | Common Stock | D | 0,3800 | 2.500 | 1 | 11.097.141 | ||||
| 2017-04-07 | 2017-04-07 | 4 | Ramelli Joseph W. | MRNA | Common Stock | D | 0,4250 | 22.500 | 10 | 440.653 | ||||
| 2017-04-07 | 2017-04-06 | 4 | Ramelli Joseph W. | MRNA | Common Stock | D | 0,3360 | 13.000 | 4 | 418.153 | ||||
| 2017-04-05 | 2017-04-05 | 4 | Ramelli Joseph W. | MRNA | Common Stock | D | 0,3120 | 97.550 | 30 | 405.153 | ||||
| 2017-02-14 | 2017-02-13 | 4 | Hwang Larn | MRNA | Options to purchase common stock | D | 0,18 | 60.000 | 60.000 | |||||
| 2017-02-14 | 2017-02-13 | 4 | Munsif Mihir | MRNA | Options to purchase common stock | D | 0,18 | 60.000 | 60.000 | |||||
| 2017-02-08 | 2017-02-06 | 4 | Trieu Vuong | MRNA | Common Stock | I | 0,2900 | 862.068 | 250 | 862.068 | ||||
| 2017-02-03 | 2017-02-02 | 4 | Ramelli Joseph W. | MRNA | Common Stock | D | 100.000 | 307.603 | ||||||
| 2017-01-04 | 2017-01-03 | 4 | Calais Philippe | MRNA | Options to purchase common stock | D | 0,17 | 81.000 | 81.000 | |||||
| 2017-01-04 | 2017-01-03 | 4 | Loren Stefan | MRNA | Options to purchase common stock | D | 0,17 | 81.000 | 81.000 | |||||
| 2017-01-04 | 2017-01-03 | 4 | Ranker Philip C | MRNA | Options to purchase common stock | D | 0,17 | 81.000 | 81.000 | |||||
| 2017-01-04 | 2017-01-03 | 4 | Trieu Vuong | MRNA | Options to purchase common stock | D | 0,17 | 81.000 | 81.000 | |||||
| 2017-01-04 | 2017-01-03 | 4 | Williams Donald Allen | MRNA | Options to purchase common stock | D | 0,17 | 81.000 | 81.000 | |||||
| 2017-01-04 | 2017-01-03 | 4 | Ramelli Joseph W. | MRNA | Options to purchase common stock | D | 0,17 | 81.000 | 81.000 | |||||
| 2016-11-25 | 3 | Autotelic LLC | MRNA | Common Stock | D | 46.247.116 | ||||||||
| 2016-11-25 | 3 | Autotelic LLC | MRNA | Common Stock | D | 46.247.116 | ||||||||
| 2016-11-22 | 2016-11-15 | 4 | Trieu Vuong | MRNA | Common Stock | I | 5.255.354 | 5.255.354 | ||||||
| 2016-11-22 | 2016-11-15 | 4 | Trieu Vuong | MRNA | Common Stock | I | 23.123.558 | 23.123.558 | ||||||
| 2016-11-22 | 2016-11-15 | 4 | Trieu Vuong | MRNA | Common Stock | D | 11.094.641 | 11.094.641 | ||||||
| 2016-11-17 | 2016-11-15 | 4 | Ramelli Joseph W. | MRNA | Options to purchase common stock | D | 0,10 | 35.000 | 35.000 | |||||
| 2016-11-17 | 2016-11-15 | 4 | Ranker Philip C | MRNA | Options to purchase common stock | D | 0,10 | 35.000 | 35.000 | |||||
| 2016-11-17 | 2016-11-15 | 4 | Loren Stefan | MRNA | Options to purchase common stock | D | 0,10 | 35.000 | 35.000 | |||||
| 2016-11-17 | 2016-11-15 | 4 | Williams Donald Allen | MRNA | Options to purchase common stock | D | 0,10 | 35.000 | 35.000 | |||||
| 2016-01-05 | 2016-01-04 | 4 | Williams Donald Allen | MRNA | Options to purchase common stock | D | 0,26 | 38.000 | 38.000 | |||||
| 2016-01-05 | 2016-01-04 | 4 | Ramelli Joseph W. | MRNA | Options to purchase common stock | D | 0,26 | 38.000 | 38.000 | |||||
| 2016-01-05 | 2016-01-04 | 4 | Loren Stefan | MRNA | Options to purchase common stock | D | 0,26 | 38.000 | 38.000 | |||||
| 2016-01-05 | 2016-01-04 | 4 | Ranker Philip C | MRNA | Options to purchase common stock | D | 0,26 | 38.000 | 38.000 | |||||
| 2015-01-07 | 2015-01-06 | 4 | Ranker Philip C | MRNA | Options to purchase common stock | D | 0,64 | 38.000 | 38.000 | |||||
| 2015-01-07 | 2015-01-06 | 4 | Williams Donald Allen | MRNA | Options to purchase common stock | D | 0,64 | 38.000 | 38.000 | |||||
| 2015-01-07 | 2015-01-06 | 4 | Ramelli Joseph W. | MRNA | Options to purchase common stock | D | 0,64 | 38.000 | 38.000 | |||||
| 2015-01-07 | 2015-01-06 | 4 | Loren Stefan | MRNA | Options to purchase common stock | D | 0,64 | 38.000 | 38.000 | |||||
| 2015-01-02 | 2014-12-30 | 4 | FRENCH J MICHAEL | MRNA | Common Stock | D | 0,3300 | -309.055 | -102 | 822.283 | ||||
| 2014-09-19 | 2014-09-15 | 4 | Williams Donald Allen | MRNA | Options to purchase common stock | D | 1,07 | 62.000 | 62.000 | |||||
| 2014-09-17 | 2014-09-15 | 4 | FRENCH J MICHAEL | MRNA | Options to purchase common stock | D | 1,07 | 771.000 | 771.000 | |||||
| 2014-09-17 | 2014-09-15 | 4 | Ramelli Joseph W. | MRNA | Options to purchase common stock | D | 1,07 | 62.000 | 62.000 | |||||
| 2014-09-17 | 2014-09-15 | 4 | Ranker Philip C | MRNA | Options to purchase common stock | D | 1,07 | 62.000 | 62.000 | |||||
| 2014-09-17 | 2014-09-15 | 4 | Loren Stefan | MRNA | Options to purchase common stock | D | 1,07 | 62.000 | 62.000 | |||||
| 2014-04-18 | 2014-04-16 | 4 | Ramelli Joseph W. | MRNA | Common Stock | D | 0,7604 | 26.300 | 20 | 207.603 | ||||
| 2014-02-10 | 2014-02-10 | 4 | Pryor Cashman LLP | MRNA | common stock, par value $0.006 per share | D | 1,0180 | -15.000 | -15 | 1.591.959 | ||||
| 2014-02-10 | 2014-02-07 | 4 | Pryor Cashman LLP | MRNA | common stock, par value $0.006 per share | D | 1,0070 | -59.000 | -59 | 1.606.959 | ||||
| 2014-02-10 | 2014-02-06 | 4 | Pryor Cashman LLP | MRNA | common stock, par value $0.006 per share | D | 0,9490 | -34.041 | -32 | 1.665.959 | ||||
| 2014-01-06 | 2014-01-01 | 4 | FRENCH J MICHAEL | MRNA | Common Stock | D | 1.131.000 | 1.132.338 | ||||||
| 2014-01-06 | 2014-01-01 | 4 | Ranker Philip C | MRNA | Common Stock | D | 897.303 | 897.553 | ||||||
| 2014-01-06 | 2014-01-01 | 4 | Loren Stefan | MRNA | Common Stock | D | 181.303 | 181.303 | ||||||
| 2014-01-06 | 2014-01-01 | 4 | Ho Richard Theodore | MRNA | Common Stock | D | 390.000 | 390.000 | ||||||
| 2014-01-06 | 2014-01-01 | 4 | Ramelli Joseph W. | MRNA | Common Stock | D | 181.303 | 181.303 | ||||||
| 2013-10-04 | 2013-10-04 | 4 | Pryor Cashman LLP | MRNA | common stock, par value $0.006 per share | D | 0,2381 | -35.000 | -8 | 1.700.000 | ||||
| 2013-10-04 | 2013-10-03 | 4 | Pryor Cashman LLP | MRNA | common stock, par value $0.006 per share | D | 0,2513 | -65.000 | -16 | 1.735.000 | ||||
| 2012-08-31 | 3 | Pryor Cashman LLP | MRNA | Common Stock, par value $0.006 per share | D | 1.800.000 | ||||||||
| 2011-09-08 | 3 | Ranker Philip C | MRNA | Marina Biotech Common Stcok | D | 2.500 | ||||||||
| 2010-07-23 | 3 | Parker Peter | MRNA | Marina Biotech Common Stock | D | 7.957 | ||||||||
| 2010-07-23 | 3 | LI CHIANG J | MRNA | Marina Biotech Common Stock | D | 62.395 | ||||||||
| 2007-10-09 | 3 | Costantino Henry R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 369 | ||||||||
| 2007-10-09 | 3 | Costantino Henry R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 304 | ||||||||
| 2007-10-09 | 3 | Costantino Henry R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 1.434 | ||||||||
| 2007-10-09 | 3 | Costantino Henry R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 582 | ||||||||
| 2007-10-09 | 3 | Costantino Henry R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 2.733 | ||||||||
| 2007-10-09 | 3 | Costantino Henry R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 5.000 | ||||||||
| 2007-10-09 | 3 | Costantino Henry R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 215 | ||||||||
| 2006-06-15 | 2006-06-13 | 4 | BAYH SUSAN B | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 13,36 | 13,3600 | 8.000 | 107 | 23.000 | |||
| 2006-06-15 | 2006-06-13 | 4 | BAYH SUSAN B | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 5.235 | 20.235 | ||||||
| 2006-06-15 | 2006-06-13 | 4 | BEESE J CARTER JR | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 13,36 | 13,3600 | 10.000 | 134 | 72.500 | |||
| 2006-06-15 | 2006-06-13 | 4 | BEESE J CARTER JR | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 5.000 | 12.500 | ||||||
| 2006-06-15 | 2006-06-13 | 4 | CROSS ALEXANDER D | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 13,36 | 13,3600 | 10.000 | 134 | 26.500 | |||
| 2006-06-15 | 2006-06-13 | 4 | CROSS ALEXANDER D | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 5.000 | 22.500 | ||||||
| 2006-06-15 | 2006-06-13 | 4 | FERRIER IAN R | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 13,36 | 13,3600 | 4.000 | 53 | 20.000 | |||
| 2006-06-15 | 2006-06-13 | 4 | FERRIER IAN R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 3.235 | 9.235 | ||||||
| 2006-06-15 | 2006-06-13 | 4 | HOLUBIAK MYRON Z | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 13,36 | 13,3600 | 9.500 | 127 | 27.500 | |||
| 2006-06-15 | 2006-06-13 | 4 | HOLUBIAK MYRON Z | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 5.735 | 23.735 | ||||||
| 2006-06-07 | 2006-06-07 | 4 | THAW BRUCE R/FA | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 8,25 | 8,2500 | -10.000 | -82 | 86.000 | |||
| 2006-06-07 | 2006-06-07 | 4 | THAW BRUCE R/FA | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,0000 | -10.000 | -140 | 104.041 | ||||
| 2006-06-07 | 2006-06-07 | 4 | THAW BRUCE R/FA | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 8,2500 | 10.000 | 82 | 114.041 | ||||
| 2006-05-17 | 2006-05-16 | 4 | MICHELSON LESLIE D | NSTK | Nastech Pharmaceutical Company Common Stock | D | 13,1300 | 3.000 | 39 | 37.000 | ||||
| 2006-04-07 | 2006-04-05 | 4 | Stanewick Gerald T | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 17,2500 | -3.000 | -52 | 97.212 | ||||
| 2006-03-29 | 2006-03-28 | 4 | POLLOCK JOHN V | NSTK | Nastech Pharmaceutical Stock Options | D | 8,25 | 8,2500 | -10.000 | -82 | 62.500 | |||
| 2006-03-29 | 2006-03-28 | 4 | POLLOCK JOHN V | NSTK | Nastech Pharmaceutical Common Stock | D | 8,2500 | 10.000 | 82 | 30.833 | ||||
| 2006-03-28 | 2006-03-27 | 4 | BRANDT GORDON | NSTK | Nastech Pharmaceutical Co. Inc. Common Stock | D | 18,3400 | -1.685 | -31 | 12.500 | ||||
| 2006-02-03 | 2006-01-30 | 4 | Duffy Timothy M | NSTK | Nastech Pharmaceutical Company Inc. Stock Options | D | 15,95 | 15,9500 | 19.000 | 303 | 34.000 | |||
| 2006-02-03 | 2006-01-30 | 4 | Duffy Timothy M | NSTK | Nastech Pharmaceutical Company Inc. Common Stock | D | 19.000 | 35.052 | ||||||
| 2005-12-20 | 2005-12-16 | 4 | BRANDT GORDON | NSTK | Nastech Pharmaceutical Company Stock Options | D | 15,31 | 15,3100 | 7.500 | 115 | 130.000 | |||
| 2005-12-20 | 2005-12-16 | 4 | BRANDT GORDON | NSTK | Nastech Pharmaceutical Co. Common Stock | D | 7.500 | 15.000 | ||||||
| 2005-10-07 | 2005-10-05 | 4 | JOHNSON PAUL H | NSTK | Nastech Pharmaceutical Co. Stock Options | D | 14,79 | 14,7900 | 7.500 | 111 | 101.500 | |||
| 2005-10-07 | 2005-10-05 | 4 | JOHNSON PAUL H | NSTK | Nastech Pharmaceutical Co. Common Stock | D | 7.500 | 11.500 | ||||||
| 2005-10-03 | 2005-10-03 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,2700 | -200 | -3 | 366.487 | ||||
| 2005-10-03 | 2005-10-03 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,2000 | -100 | -1 | 366.687 | ||||
| 2005-10-03 | 2005-10-03 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,1500 | -200 | -3 | 366.787 | ||||
| 2005-10-03 | 2005-10-03 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,1000 | -200 | -3 | 366.987 | ||||
| 2005-10-03 | 2005-10-03 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,0600 | -100 | -1 | 367.187 | ||||
| 2005-10-03 | 2005-10-03 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,0500 | -100 | -1 | 367.287 | ||||
| 2005-10-03 | 2005-10-03 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 14,0000 | -100 | -1 | 367.387 | ||||
| 2005-09-22 | 2005-09-22 | 4 | WORMUTH DAVID E | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 4,62 | 4,6250 | -5.000 | -23 | 100.000 | |||
| 2005-09-22 | 2005-09-22 | 4 | WORMUTH DAVID E | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 13,6800 | -5.000 | -68 | 7.500 | ||||
| 2005-09-22 | 2005-09-22 | 4 | WORMUTH DAVID E | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 4,6250 | 5.000 | 23 | 12.500 | ||||
| 2005-09-12 | 3 | Ranker Philip C | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 792 | ||||||||
| 2005-09-12 | 3 | Ranker Philip C | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 15.000 | ||||||||
| 2005-09-12 | 3 | Ranker Philip C | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 2.175 | ||||||||
| 2005-09-12 | 3 | YORK BRUCE R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 2.000 | ||||||||
| 2005-09-12 | 3 | YORK BRUCE R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 10.000 | ||||||||
| 2005-09-12 | 3 | YORK BRUCE R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 1.137 | ||||||||
| 2005-09-12 | 3 | YORK BRUCE R | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 612 | ||||||||
| 2005-09-12 | 3/A | Ranker Philip C | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 2.175 | ||||||||
| 2005-09-12 | 3/A | Ranker Philip C | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 792 | ||||||||
| 2005-09-12 | 3/A | Ranker Philip C | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 15.000 | ||||||||
| 2005-07-22 | 2005-07-20 | 4 | BAYH SUSAN B | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 14,72 | 14,7200 | 15.000 | 221 | 15.000 | |||
| 2005-07-22 | 2005-07-20 | 4 | BAYH SUSAN B | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 15.000 | 15.000 | ||||||
| 2005-07-22 | 3 | CROSS ALEXANDER D | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 1.000 | ||||||||
| 2005-07-22 | 2005-07-20 | 4 | CROSS ALEXANDER D | NSTK | Nastech Pharmaceutical Company Inc Stock Options | D | 14,72 | 14,7200 | 16.500 | 243 | 16.500 | |||
| 2005-07-22 | 2005-07-20 | 4 | CROSS ALEXANDER D | NSTK | Nastech Pharmaceutical Company Inc Common Stock | D | 16.500 | 17.500 | ||||||
| 2003-10-02 | 2003-10-01 | 4 | WENIG DEVIN | NSTK | Nastech Pharmaceutical Co. Common Stock | D | 10,0000 | -1.000 | -10 | 229.153 |
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)
